Evidence Base
Clinical Outcomes
Our protocols are based on decades of clinical research demonstrating remarkable efficacy for treatment-resistant conditions.
60-80%
Addiction Interruption
Ibogaine for opioids
67%
Depression Remission
Psilocybin therapy
67%
PTSD Resolution
MDMA-assisted
83%
Reduced Heavy Drinking
Psilocybin therapy
Research-Backed Outcomes
Condition
Opioid Addiction
Ibogaine Protocol
Success Rate
60-80%
Addiction Interruption
Evidence
Single ibogaine treatment eliminates acute withdrawal symptoms and interrupts addiction patterns in the majority of patients.
Source: Brown & Alper, 2018
Condition
Treatment-Resistant Depression
Psilocybin Therapy
Success Rate
67%
Remission at 3 Weeks
Evidence
Patients who had not responded to multiple antidepressants showed significant improvement after psilocybin treatment.
Source: COMPASS Pathways, 2022
Condition
PTSD
MDMA-Assisted Therapy
Success Rate
67%
No Longer Meet Diagnosis
Evidence
Two-thirds of treatment-resistant PTSD patients no longer met diagnostic criteria after MDMA-assisted therapy.
Source: MAPS Phase 3, 2021
Condition
Alcohol Use Disorder
Psilocybin Therapy
Success Rate
83%
Reduction in Heavy Drinking
Evidence
Participants showed an 83% reduction in heavy drinking days compared to 51% in placebo group.
Source: Bogenschutz et al., 2022
Patient Stories
"After 15 years of opioid addiction and countless failed rehabs, one ibogaine treatment gave me my life back. I've been clean for 3 years now."
Former Patient, Opioid Addiction
3 Years Clean
"I tried every antidepressant on the market. Nothing worked. One psilocybin session did more than a decade of pharmaceuticals."
Former Patient, Treatment-Resistant Depression
In Remission
"As a combat veteran, I thought PTSD was my life sentence. This treatment gave me peace I didn't know was possible."
Former Patient, PTSD
Symptom-Free
* Testimonials represent individual experiences. Results vary by patient.
Our Outcome Tracking
We use validated clinical instruments to measure outcomes at baseline and follow-up intervals, enabling continuous protocol improvement.
| Instrument | Baseline | Follow-Up |
|---|---|---|
| PHQ-9 (Depression) | Pre-treatment | 3, 6, 12 months |
| GAD-7 (Anxiety) | Pre-treatment | 3, 6, 12 months |
| PCL-5 (PTSD) | Pre-treatment | 3, 6, 12 months |
| AUDIT (Alcohol) | Pre-treatment | 3, 6, 12 months |
| Quality of Life (WHO-5) | Pre-treatment | 3, 6, 12 months |
| MEQ30 (Mystical Experience) | Post-session | N/A |
Integration Success Factors
Pre-treatment preparation
Proper intention setting and psychological readiness
Medical screening
Identifying contraindications and risk factors
Set and setting
Optimal environment for therapeutic experience
Integration support
Post-treatment coaching and community
Lifestyle changes
Nutrition, exercise, and sleep optimization
Commitment to Research
We are committed to contributing to the growing body of evidence on psychedelic therapy. Our outcome data will support the broader movement toward mainstream acceptance and accessibility.
Data Collection
Standardized instruments at all touchpoints
Analysis
Regular outcome analysis and protocol refinement
Publication
Contributing to peer-reviewed research